Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow 10x Genomics, Inc.

Get SEC filing alerts via email and in your feed for 10x Genomics, Inc.

TXG

10x Genomics, Inc.

About 10x Genomics, Inc.

10x Genomics, Inc. is a life sciences technology company dedicated to advancing human health through innovative biological analysis solutions. Its key products, including the Chromium, Visium, and Xenium platforms, enable high-resolution single-cell and spatial analysis. With a $21 billion addressable market, 10x targets academic, biopharmaceutical, and research institutions. The company emphasizes R&D and customer collaboration to drive product development, aiming to enhance biological understanding and discovery across various fields.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from 10x Genomics, Inc.

1
1
10x Genomics, Inc. 10x Genomics Reports Q1 2026 Revenue of $150.8M, Net Loss of $13.5M

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
10x Genomics, Inc. 10x Genomics Reports 5% Revenue Increase to $642.8 Million in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
10x Genomics, Inc. 10x Genomics Reports Q3 2025 Revenue of $149M, Net Loss of $27.5M

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
10x Genomics, Inc. 10x Genomics Reports 13% Revenue Growth in Q2 2025, Net Income Recovery

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
10x Genomics, Inc. 10x Genomics Reports 10% Revenue Growth to $154.9 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
10x Genomics, Inc. 10x Genomics Reports 1% Revenue Decline and Improved Net Losses for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
10x Genomics, Inc. 10x Genomics Reports Mixed Q3 2024 Results with Decreased Instrument Sales and Improved Profitability

Via official filing (AI summary) | over 1 year ago | 0 comments